2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2129

Thyroperoxidase Antibodies in Patients with Positive ANA
Abstract Number: 2130

Enrichment of IL-17-producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis After anti-CTLA-4 and anti-PD-1 Combination Therapy
Abstract Number: 2131

Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases
Abstract Number: 2132

Complement Component 3 as Biomarker of Cardiometabolic Risk in Rheumatic Diseases: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Systemic Lupus Erythematosus
Abstract Number: 2133

Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Abstract Number: 2134

Extracellular Adenosine Increases IL-6 Production by Aging Tenocytes and May Contribute to the Age-related Pattern of Polymyalgia Rheumatica
Abstract Number: 2135

Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features
Abstract Number: 2136

Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology
Abstract Number: 2137

Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma
Abstract Number: 2138

Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population
Abstract Number: 2139

Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases
Abstract Number: 2140

Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Abstract Number: 2141

Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients
Abstract Number: 2142

Frailty in Systemic Rheumatic Diseases: A Systematic Review
Abstract Number: 2143

Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].